SCHEMBL1198640

SCHEMBL1198640

Fc1ccnc(Br)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383108 0.72
SCHEMBL138862 0.72
SCHEMBL2174027 0.70
Water SCHEMBL9342594 0.70 LOXL2 (0.33)
Water SCHEMBL9342567 0.70
SCHEMBL1337601 0.69 ADRB1 (0.43)
SCHEMBL28229628 0.69 IDH1 (0.36)
SCHEMBL25468838 0.68
SCHEMBL18366964 0.68
SCHEMBL14230908 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570642-B2 GLP-IR modulating compounds GILEAD SCIENCES, INC. (US) 2026-03-10 US disclosed
EP-4691554-A2 GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 EP disclosed
EP-4271672-B1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 EP disclosed
US-20250223278-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-07-10 US disclosed
US-12240831-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-03-04 US disclosed
US-12240833-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-03-04 US disclosed
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-20 US disclosed
US-12012395-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2024-06-18 US disclosed
EP-3877367-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2024-05-22 EP disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 US disclosed
WO-2012170845-A2 METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF HEFFERNAN MICHELE L R (US) 2012-12-13 WO disclosed
CN-101370784-B Compound serving as ERK inhibitors SCHERING CORPORTAION 2012-10-10 CN disclosed
EP-1966151-B1 POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS SCHERING CORP (US) 2011-10-05 EP disclosed
US-20110038876-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS SCHERING CORPORATION 2011-02-17 US disclosed
CN-101772501-A Heterocyclic compounds and their use as ERK inhibitors SCHERING CORP 2010-07-07 CN disclosed
EP-2170893-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS SCHERING CORPORATION (US) 2010-04-07 EP disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed
CN-101370784-A Polycyclic indazole derivatives that are erk inhibitors SCHERING CORP (US) 2009-02-18 CN disclosed
WO-2008156739-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS SCHERING CORPORATION (US) 2008-12-24 WO disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 US disclosed